Is Enliven Therapeutics, Inc. (ELVN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 17.9% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 17.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 96.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 17.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 96.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -27.0% | |
| Return on Assets (ROA) | -18.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$70M |
| Free Cash Flow | -$70M |
| Total Debt | $399,000 |
| Debt-to-Equity | 0.1 |
| Current Ratio | 28.7 |
| Total Assets | $476M |
Price & Trading
| Last Close | $39.29 |
| 50-Day MA | $28.53 |
| 200-Day MA | $22.27 |
| Avg Volume | 1.1M |
| Beta | 1.1 |
|
52-Week Range
$13.30
| |
About Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Enliven Therapeutics, Inc. (ELVN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Enliven Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Enliven Therapeutics, Inc.'s debt ratio?
Enliven Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Enliven Therapeutics, Inc.'s key financial metrics?
Enliven Therapeutics, Inc. has a market capitalization of $2.3B. Return on equity stands at -27.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.